Stellungnahme der retinologischen gesellschaft, der Deutschen ophthalmologischen gesellschaft und des berufsverbands der augenärzte Deutschlands zu aktuellen therapeutischen möglichkeiten bei der neovaskulären altersabhängigen makuladegeneration: Stand Juni 2007

Translated title of the contribution: Position of the retinological society, the German ophthalmological society and the professional association of ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration: Status as of june 2007

U. Bartz-Schmidt*, B. Bertram, N. Bornfeld, S. Grisanti, F. Holz, K. Lemmen, D. Pauleikhoff, J. Roider, P. Walter

*Corresponding author for this work
21 Citations (Scopus)

Abstract

The basic conditions in the management of exudative age-related macular degeneration have changed considerably since the last statement of the German professional associations in 2006. While Pegaptanib was approved in Germany already in 2006 Ranibizumab was approved for the treatment of exudative macular degeneration in Germany in February 2007. More over the quality assurance regulations for the photodynamic treatment of choroidal neovascularizations with Verteporfin were modified including the treatment of occult lesions and implementing a simplified classification of extra- and subfoveal lesions. Consequently modification of the recommendations for the non-surgical treatment of exudative age-related macular degeneration appeared inevitable.

Translated title of the contributionPosition of the retinological society, the German ophthalmological society and the professional association of ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration: Status as of june 2007
Original languageGerman
JournalKlinische Monatsblatter fur Augenheilkunde
Volume224
Issue number7
Pages (from-to)559-566
Number of pages8
ISSN0023-2165
DOIs
Publication statusPublished - 07.2007

Fingerprint

Dive into the research topics of 'Position of the retinological society, the German ophthalmological society and the professional association of ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration: Status as of june 2007'. Together they form a unique fingerprint.

Cite this